Literature DB >> 24989136

Stable expression and characterization of monomeric and dimeric recombinant hybrid-IgG/IgA immunoglobulins specific for Shiga toxin.

Koki Iwata1, Kohta Kurohane, Katsuhiro Nakanishi, Masaki Miyake, Yasuyuki Imai.   

Abstract

Antigen-specific immunoglobulin A (IgA) may be useful for preventing infectious diseases through passive immunization on the mucosal surface. We previously established mouse IgA and IgG monoclonal antibodies (mAbs) specific for the binding subunit of Shiga toxin 1 (Stx1B). We also developed a recombinant hybrid-IgG/IgA, in which variable regions from the IgG mAb were present. The binding activity of recombinant hybrid-IgG/IgA was verified by transient expression. Aiming at a constant supply, we established Chinese hamster ovary cells stably expressing monomeric or dimeric hybrid-IgG/IgA. The cDNAs encoding heavy and light chains were co-expressed for the monomeric hybrid-IgG/IgA, while those encoding heavy, light, and joining chains were co-expressed for the dimeric one. Serum-free culture supernatants of the cloned transfectants were subjected to size-exclusion chromatography. The elution patterns showed that the binding to immobilized Stx1B and the immunoblot signals of assembled immunoglobulins were correlated. In the transfectant for the dimeric hybrid-IgG/IgA, both monomers and dimers were observed. Size-exclusion chromatography enabled us to prepare a sample of the dimeric hybrid-IgG/IgA devoid of the monomeric one. The monomeric and dimeric forms of hybrid-IgG/IgA were prepared from the respective transfectants to examine the neutralization of Stx1. After pretreatment with monomeric or dimeric hybrid-IgG/IgA, the cytotoxicity of Stx1 toward Vero cells was abolished. Furthermore, the dimeric form was more than 10-fold more effective than the monomeric one in terms of toxin neutralization. These results suggest that the tetravalent feature of the binding sites of the dimeric hybrid-IgG/IgA contributes to the efficacy of toxin neutralization.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24989136     DOI: 10.1248/bpb.b14-00323

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  Strategies to avoid Shiga toxin effects.

Authors:  Analia Etcheverria
Journal:  Virulence       Date:  2015       Impact factor: 5.882

2.  Shiga toxin-induced apoptosis is more efficiently inhibited by dimeric recombinant hybrid-IgG/IgA immunoglobulins than by the parental IgG monoclonal antibodies.

Authors:  Kohta Kurohane; Kyoko Nagano; Katsuhiro Nakanishi; Koki Iwata; Masaki Miyake; Yasuyuki Imai
Journal:  Virulence       Date:  2014       Impact factor: 5.882

3.  Recombinant immunoglobulin A specific for influenza A virus hemagglutinin: production, functional analysis, and formation of secretory immunoglobulin A.

Authors:  Kentaro Shoji; Tadanobu Takahashi; Kohta Kurohane; Koki Iwata; Takeshi Matsuoka; Shogo Tsuruta; Takatomo Sugino; Masaki Miyake; Takashi Suzuki; Yasuyuki Imai
Journal:  Viral Immunol       Date:  2015-02-06       Impact factor: 2.257

4.  Plant-derived secretory component gives protease-resistance to Shiga toxin 1-specific dimeric IgA.

Authors:  Katsuhiro Nakanishi; Noriko Mogi; Yuki Kikuchi; Minami Matsuda; Takeshi Matsuoka; Kotome Shiina; Shota Morikane; Kohta Kurohane; Yasuo Niwa; Hirokazu Kobayashi; Yasuyuki Imai
Journal:  Plant Mol Biol       Date:  2021-04-19       Impact factor: 4.076

5.  Protection of Human Colon Cells from Shiga Toxin by Plant-based Recombinant Secretory IgA.

Authors:  Katsuhiro Nakanishi; Shota Morikane; Shiori Ichikawa; Kohta Kurohane; Yasuo Niwa; Yoshihiro Akimoto; Sachie Matsubara; Hayato Kawakami; Hirokazu Kobayashi; Yasuyuki Imai
Journal:  Sci Rep       Date:  2017-04-03       Impact factor: 4.379

Review 6.  Therapeutic Antibodies Against Shiga Toxins: Trends and Perspectives.

Authors:  Izabella de Macedo Henrique; Flavia Sacerdoti; Raissa Lozzardo Ferreira; Camila Henrique; Maria Marta Amaral; Roxane Maria Fontes Piazza; Daniela Luz
Journal:  Front Cell Infect Microbiol       Date:  2022-02-10       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.